热门资讯> 正文
诺和诺德向FDA提交血友病治疗申请审查
2025-09-29 21:33
- Novo Nordisk (NVO) said that it has filed a biologic marketing application for Mim8 (denecimig) with the US FDA as a treatment to help prevent or lessen bleeding episodes in individuals with hemophilia A.
- The submission is based on findings from the FRONTIER study program, which was created to demonstrate the effectiveness and safety of denecimig.
More on Novo Nordisk
- Novo Nordisk: Wegovy Sales Soar, Trump Tariffs No Threat
- Novo Nordisk: Don't Be Deterred By Outlook Downgrades
- Novo Nordisk: Attractive Buying Opportunity In A Distracted Market
- Trump’s 100% drug tariffs send pharma stocks lower
- Novo Nordisk reduces its U.S. sales team for obesity and diabetes education: Reuters
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。